Elevance Health stock gains on leadership shake-up and solid earnings
Published on 09/01/2026 at 17:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health Inc. (ISIN US0367521038) stock is trading close to the upper tier of its 52-week range, with the shares around USD 392 at the latest completed session as of August 31, 2026, highlighting continued investor confidence in the managed care group’s earnings power.
Leadership changes add a new angle for investors
On September 1, 2026, Elevance Health unveiled a series of senior leadership appointments across its Health Benefits segment and Carelon services unit, giving investors fresh signals on how the company plans to steer its growth and integration strategy in coming years, according to Fierce Healthcare.
The changes include a new president for Carelon Health and fresh leadership for Elevance’s government business and Carelon Insights, alongside new chief financial officers for Carelon and the Health Benefits segment, all announced as of late April 2026 and highlighted again in the September 1, 2026 roundup by Fierce Healthcare.
Earnings beat and margin profile support the valuation
The leadership news lands on top of a solid earnings backdrop. Elevance Health last reported quarterly earnings on July 15, 2026, delivering earnings per share (EPS) of USD 7.45 for that quarter, which was USD 1.24 above the analyst consensus of USD 6.21, according to a detailed market data summary compiled by MarketBeat.
In that same quarter, which corresponds to the company’s most recent reported period in 2026, Elevance Health generated revenue of USD 49.83 billion, slightly ahead of analyst expectations of USD 48.88 billion, reflecting a revenue beat of USD 0.95 billion and year over year revenue growth of 0.8 percent as noted in the MarketBeat data.
The quarter also showed a net margin of 2.47 percent and a return on equity of 14.64 percent, underlining that Elevance converts its large revenue base into modest but consistent profitability while using shareholder capital efficiently, according to the same MarketBeat overview.
For comparison, analysts as a group currently expect Elevance Health to deliver EPS of 27.18 for the full current fiscal year 2026, based on MarketBeat’s consensus compilation, implying that the July 15, 2026 quarter accounts for roughly 27 percent of the full year earnings target and that the company needs to sustain similar profit levels in the remaining quarters.
Dividend policy remains a supporting factor
Beyond earnings, Elevance Health’s dividend policy offers another pillar of the investment case. The company has declared a quarterly dividend of USD 1.72 per share, corresponding to an annualized dividend of USD 6.88 and a dividend yield of about 1.8 percent on the current share price level, with a payout ratio presently at 30.58 percent, according to MarketBeat’s same-day summary dated September 1, 2026.
For investors, this combination of a moderate dividend yield and a payout ratio around 30 percent leaves room for continued reinvestment in growth initiatives while still returning cash to shareholders, a balance that many large-cap U.S. health insurers seek to maintain.
Valuation and 52-week range set the market context
MarketBeat data as of September 1, 2026 shows that Elevance Health stock opened the latest trading day at USD 392.81, with a 52-week low of USD 274.84 and a 52-week high of USD 436.24, placing the current price closer to the top than to the bottom of that range and underscoring that the stock trades at a premium versus last year’s trough.
On August 31, 2026, a separate market commentary by Yahoo Finance noted that Elevance Health closed at USD 392.54 per share, indicating only a narrow difference between the opening price on September 1, 2026 and the previous closing price, so the shares have been relatively stable around the high USD 390s in recent sessions.
At a price in the high USD 390s and with analysts projecting EPS of 27.18 for fiscal year 2026, Elevance Health is implicitly valued at a forward price to earnings multiple of around 14.5 times, a level that aligns the company with other large-cap managed care peers that combine scale and steady profit growth.
More on Elevance Health stock
For a broader overview of Elevance Health’s share price, fundamentals and recent filings, the issuer page at ad-hoc-news.de offers an aggregated view of news and market data for the ISIN US0367521038.
Carelon services as a strategic product pillar
A key product and business pillar for Elevance Health is its Carelon platform, which bundles services such as pharmacy benefits management, behavioral health support and value based care enablement, according to Fierce Healthcare’s September 1, 2026 overview.
Within Carelon, the appointment of a new president for Carelon Health, alongside a leader for Carelon Insights and a dedicated chief financial officer, signals that Elevance continues to invest in service capabilities that complement its core insurance and health benefits offerings and that can generate fee based revenue streams.
Stock perspective at the current price level
As of the latest available close on August 31, 2026 cited by Yahoo Finance, Elevance Health stock stood at USD 392.54 on the New York Stock Exchange, a level that keeps the shares within the upper segment of their 52-week price corridor of USD 274.84 to USD 436.24, based on MarketBeat’s September 1, 2026 figures.
Elevance Health stock facts
- Company: Elevance Health Inc.
- ISIN: US0367521038
- Ticker: ELV
- Trading venue: NYSE
- Price (as of August 31, 2026): 392.54 USD
- Market capitalization: tens of billions USD (as of September 1, 2026)
- Sector / Industry: Health Care / Managed Care
- Index membership: S&P 500
